Trillium Asset Management LLC Cuts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Trillium Asset Management LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 83,329 shares of the medical research company's stock after selling 4,366 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.1% of Trillium Asset Management LLC's investment portfolio, making the stock its 18th largest holding. Trillium Asset Management LLC's holdings in Thermo Fisher Scientific were worth $43,351,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Howard Capital Management Group LLC raised its stake in shares of Thermo Fisher Scientific by 0.5% during the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock worth $33,759,000 after purchasing an additional 286 shares during the period. Principal Financial Group Inc. increased its stake in shares of Thermo Fisher Scientific by 22.1% in the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after purchasing an additional 225,568 shares in the last quarter. GLOBALT Investments LLC GA increased its stake in shares of Thermo Fisher Scientific by 5.0% in the third quarter. GLOBALT Investments LLC GA now owns 1,102 shares of the medical research company's stock worth $682,000 after purchasing an additional 52 shares in the last quarter. Baron Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 2.1% in the third quarter. Baron Wealth Management LLC now owns 1,345 shares of the medical research company's stock worth $832,000 after purchasing an additional 28 shares in the last quarter. Finally, Aviance Capital Partners LLC grew its stake in Thermo Fisher Scientific by 0.4% during the third quarter. Aviance Capital Partners LLC now owns 13,322 shares of the medical research company's stock valued at $8,240,000 after acquiring an additional 54 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several brokerages recently commented on TMO. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Citigroup cut their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target for the company in a research note on Friday, January 10th. Bank of America cut their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Finally, Wells Fargo & Company boosted their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $653.23.

Thermo Fisher Scientific Trading Down 0.1 %

Thermo Fisher Scientific stock traded down $0.60 during mid-day trading on Friday, reaching $518.04. 2,159,706 shares of the company traded hands, compared to its average volume of 1,540,546. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm's 50 day moving average price is $546.15 and its 200 day moving average price is $555.91. The firm has a market capitalization of $195.44 billion, a price-to-earnings ratio of 31.34, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific's payout ratio is presently 10.41%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.